Abstract：
Long-acting therapy of cabotegravir and rilpivirine is expected to free people from the negative emotions of living with HIV associated with taking drugs, but problems such as increased number of hospital visits, lack of anti-HBV activity, and limited convenience in people with concomitant drugs have been noted. In this single-center, prospective, cross-sectional study, we investigated background factors of people living with HIV in Japan who chose cabotegravir plus rilpivirine. Forty-seven percent (36 of 76) of individuals chose this regimen, but many people living with HIV who visited the hospital once every 3 months or needed concomitant medications due to complications chose this regimen and there were no significant differences in background factors that could affect convenience between the groups of those who switched and those who did not.
摘要：
cabotegravir和rilpivirine的长效治疗有望使人们摆脱与吸毒相关的艾滋病毒感染的负面情绪，但是医院就诊次数增加等问题，缺乏抗HBV活性，并且注意到伴随药物的人的便利性有限。在这个单一中心，prospective,横断面研究，我们调查了选择cabotegravir加利匹韦林的日本HIV感染者的背景因素.47％（76人中有36人）选择了这种疗法，但是,许多每3个月到医院就诊一次或因并发症需要合并用药的HIV感染者选择了该治疗方案,并且在转换组和未转换组之间,可能影响便利性的背景因素没有显著差异.
